Management of lung nodules detected by volume CT scanning by van Klaveren, R.J. et al.
  
 University of Groningen
Management of lung nodules detected by volume CT scanning
van Klaveren, R.J.; Oudkerk, M.; Prokop, M.; Scholten, E.T.; Nackaerts, K.; Vernhout, R.; van
Iersel, C.A.; van den Bergh, K.A.M.; van't Westeinde, S.; van der Aalst, C.
Published in:
New England Journal of Medicine
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Klaveren, R. J., Oudkerk, M., Prokop, M., Scholten, E. T., Nackaerts, K., Vernhout, R., ... de Koning, H.
J. (2009). Management of lung nodules detected by volume CT scanning. New England Journal of
Medicine, 361(23), 2221-2229.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 361;23 nejm.org december 3, 2009 2221
original article
Management of Lung Nodules Detected  
by Volume CT Scanning
Rob J. van Klaveren, M.D., Ph.D., Matthijs Oudkerk, M.D., Ph.D.,  
Mathias Prokop, M.D., Ph.D., Ernst T. Scholten, M.D.,  
Kristiaan Nackaerts, M.D., Ph.D., Rene Vernhout, M.Sc., Carola A. van Iersel, M.Sc., 
Karien A.M. van den Bergh, M.Sc., Susan van ’t Westeinde, M.D.,  
Carlijn van der Aalst, M.Sc., Erik Thunnissen, M.D., Ph.D., Dong Ming Xu, M.D., Ph.D., 
Ying Wang, M.D., Yingru Zhao, M.D., Hester A. Gietema, M.D., Ph.D.,  
Bart-Jan de Hoop, M.D., Harry J.M. Groen, M.D., Ph.D.,  
Geertruida H. de Bock, Ph.D., Peter van Ooijen, Ph.D., Carla Weenink, M.D.,  
Johny Verschakelen, M.D., Ph.D., Jan-Willem J. Lammers, M.D., Ph.D.,  
Wim Timens, M.D., Ph.D., Dik Willebrand, M.D., Aryan Vink, M.D.,  
Willem Mali, M.D., Ph.D., and Harry J. de Koning, M.D., Ph.D.
From the Departments of Pulmonology 
(R.J.K., R.V., C.A.I., S.W., C.A.) and Public 
Health (C.A.I., K.A.M.B., C.A., H.J.K.), 
Erasmus Medical Center, Rotterdam; the 
Departments of Radiology (M.O., D.M.X., 
Y.W., Y.Z., P.O.), Epidemiology (G.H.B.), 
Pulmonology (H.J.M.G.), and Pathology 
(W.T.), University Medical Center, Gro-
ning en; the Departments of Radiology, 
(M.P., H.A.G., B.-J.H., W.M.), Pulmonology 
(J.-W.J.L.), and Pathology (A.V.), Univer-
sity Medical Center, Utrecht; the Depart-
ments of Radiology (E.T.S.), Pulmonology 
(C.W.), and Pathology (D.W.), Kennemer 
Gasthuis, Haarlem; and the Department 
of Pathology, Free University Medical Cen-
ter Amsterdam, Amsterdam (E.T.) — all 
in the Netherlands; and the Departments 
of Pulmonology (K.N.) and Radiology (J.V.), 
University Hospital Gasthuisberg Leuven, 
Leuven, Belgium. Address reprint re-
quests to Dr. van Klaveren at the Depart-
ment of Pulmonology, Erasmus Medical 
Center, 3000 CA Rotterdam, the Nether-
lands, or at r.j.vanklaveren@erasmusmc.nl.
N Engl J Med 2009;361:2221-9.
Copyright © 2009 Massachusetts Medical Society.
A bs tr ac t
Background
The use of multidetector computed tomography (CT) in lung-cancer screening trials 
involving subjects with an increased risk of lung cancer has highlighted the prob-
lem for the clinician of deciding on the best course of action when noncalcified 
pulmonary nodules are detected by CT.
Methods
A total of 7557 participants underwent CT screening in years 1, 2, and 4 of a ran-
domized trial of lung-cancer screening. We used software to evaluate a noncalcified 
nodule according to its volume or volume-doubling time. Growth was defined as an 
increase in volume of at least 25% between two scans. The first-round screening 
test was considered to be negative if the volume of a nodule was less than 50 mm3, 
if it was 50 to 500 mm3 but had not grown by the time of the 3-month follow-up CT, 
or if, in the case of those that had grown, the volume-doubling time was 400 days 
or more.
Results
In the first and second rounds of screening, 2.6% and 1.8% of the participants, 
respectively, had a positive test result. In round one, the sensitivity of the screen 
was 94.6% (95% confidence interval [CI], 86.5 to 98.0) and the negative predictive 
value 99.9% (95% CI, 99.9 to 100.0). In the 7361 subjects with a negative screening 
result in round one, 20 lung cancers were detected after 2 years of follow-up.
Conclusions
Among subjects at high risk for lung cancer who were screened in three rounds of 
CT scanning and in whom noncalcified pulmonary nodules were evaluated accord-
ing to volume and volume-doubling time, the chances of finding lung cancer 1 and 
2 years after a negative first-round test were 1 in 1000 and 3 in 1000, respectively. 
(Current Controlled Trials number, ISRCTN63545820.)
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The use of multidetector computed tomography (CT) has increased the chance of finding noncalcified pulmonary nod-
ules,1,2 and as a result, clinicians often face the 
problem of deciding on the best course of action 
with respect to such nodules when they are found 
in asymptomatic subjects who have an increased 
risk for lung cancer.3 This difficulty is especially 
evident in CT-based screening programs for lung 
cancer. The current practice is to refer partici-
pants in these programs for additional diagnos-
tic evaluation if they have a noncalcified nodule 
that is larger than 5 mm in diameter.4-9 In design-
ing the Dutch–Belgian randomized lung cancer 
screening trial (Nederlands-Leuvens Longkanker 
Screenings Onderzoek [NELSON]), we adopted a 
strategy that was meant to provide an inexpensive 
and simple follow-up process without increasing 
the false negative rate of the screening test.10 The 
strategy entailed the use of the volume and vol-
ume-doubling time of a noncalcified nodule as 
the main criteria for deciding on further action. 
In this article, we report an evaluation of this 
strategy, which involved the tracking of indi-
vidual nodules and the collection of 2-year fol-




We randomly assigned eligible participants in 
NELSON, who were recruited as described previ-
ously,11 to undergo CT screening at baseline (first 
round), 1 year later (second round), and 3 years 
later (third round, 2 years after the second round), 
or no screening. The purpose of the trial is to 
determine whether at 10 years after randomiza-
tion CT screening will have reduced mortality 
from lung cancer by at least 25%. The trial was 
approved by the Dutch Minister of Health and 
the ethics board at each participating center. All 
participants gave written informed consent.
Screening Strategy
A 16-detector CT scanner (Somatom Sensation 16, 
Siemens Medical Solutions or, at the screening 
site in Utrecht, 1x Mx8000 IDT or Brilliance-16P, 
Philips Medical Systems) was used at each of the 
screening sites. Data sets were derived from im-
ages of the lung with a thickness of 1 mm that 
were reconstructed at overlapping 0.7-mm inter-
vals. Isotropic data sets allowed for volume mea-
surements with good reproducibility, even in the 
case of small lesions.12 Data acquisition and 
scanning conditions were standard across screen-
ing sites and were the same for all rounds of 
screening.10 At each site, CT data were analyzed 
on one type of digital workstation (Leonardo, 
Siemens Medical Solutions) with the use of soft-
ware for semiautomated volume measurements 
(LungCare, version Somaris/5 VA70C-W, Siemens 
Medical Solutions).13,14 In the case of inappropri-
ate segmentation (i.e., nodules that were attached 
to a fissure or to a vessel), the radiologist was 
allowed to enter manual measurements, which 
overruled the automatically generated volumes. 
Data generated by the LungCare software were 
uploaded into the NELSON Management System, 
which automatically detected whether a nodule 
was new or had been present previously and 
which calculated the percentage change in vol-
ume and the volume-doubling time in days (Fig. 1 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org).
A nodule was classified as noncalcified if it 
did not meet previously specified criteria for a 
benign lesion.4 For solid pleural-based and non-
solid pulmonary nodules, the diameter was deter-
mined manually, and the volume-doubling time 
was calculated as described previously10 (Fig. 1 
in the Supplementary Appendix). In the case of 
pleural-based nodules, the diameter was measured 
at a point perpendicular to the costal pleura. In 
the case of partially solid lesions, only the vol-
ume of the solid region was used. The diameter 
was defined as the average of the maximum 
length and width of the nodule. Growth was 
defined as a change in volume of at least 25% 
between the first and second scans or between 
the second and third scans. The 25% threshold 
was based on three zero-change data sets in 
which the variation in volume of individual nod-
ules was assessed between two low-dose CT 
scans. After the first of these scans, the patient 
returned to the examining table for the second 
scan to simulate the condition of a repeat exami-
nation for the follow-up of a pulmonary nodule. 
In these studies, the volume measurement error 
varied between 20% and 25%.12,14,15 Growing 
nodules were classified into three growth cate-
gories according to their volume-doubling time 
(<400, 400 to 600, and >600 days).
CT scans were independently read by first 
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and second readers. The experience of the 13 first 
readers ranged from none to more than 20 years 
of experience reading thoracic CT scans (median, 
6 years); both second readers had 6 years of ex-
perience. The second readers matched the nod-
ules they had identified with nodules identified 
by the first readers according to location and 
size and compared their results with those of 
the first readers. If the results were discrepant, 
the readers reevaluated the scan to reach a con-
sensus. If no consensus was reached, a third 
radiologist arbitrated the results.
First-Round (Baseline) Scan
A test was considered to be positive if on the CT 
scan any noncalcified nodule had a solid compo-
nent that was more than 500 mm3 (>9.8 mm in 
diameter) and was considered to be indeterminate 
if the volume of the largest solid nodule or of the 
solid component of a partially solid nodule was 
50 to 500 mm3 (4.6 to 9.8 mm in diameter) or if 
the diameter of a nonsolid nodule was greater 
than 8 mm.10 In subjects with an indeterminate 
result, a follow-up scan was obtained 3 months 
after the baseline scan to assess the growth of the 
lesion. If at that time the lesion had a volume-dou-
bling time of less than 400 days, the final result 
was declared to be positive; otherwise, it was 
considered to be negative. Subjects with positive 
screening tests were referred to a chest physician 
for workup and diagnosis. If lung cancer was di-
agnosed, the participant was treated for the dis-
ease and left the screening trial; if no lung cancer 
was found, the regular second-round CT scan was 
scheduled for 12 months after the baseline scan.
Second-Round Scan
When one or more new nodules were found on 
the second-round scan, the interpretation (posi-
tive or negative result) was based on the size of 
the nodule, as it had been in round one; if the 
result was indeterminate, a follow-up scan was 
obtained 6 weeks later.10 In the case of nodules 
that had been detected previously, the second-
round result was based on the volume-doubling 
time. If there was no growth, or if the volume-
doubling time was more than 600 days, the screen 
was classified as negative. If the volume-doubling 
time was less than 400 days, or if a new solid 
component had emerged in a previously nonsolid 
nodule, the scan was considered to be positive. 
When the volume-doubling time was 400 to 600 
days, the test result was considered to be indeter-
minate and a follow-up scan was obtained 1 year 
after the second-round scan. At that time, if the 
volume-doubling time was less than 400 days, 
the final result was considered to be positive; 
otherwise it was considered to be negative. If both 
new and existing nodules were present, the nod-
ule with the largest volume or fastest growth de-
termined the result. All participants with a neg-
ative second-round test result were invited to 
undergo the third round of screening 2 years after 
the second round. A cancer detected on screen-
ing was classified as a first-round or second-
round cancer if it was diagnosed after a workup 
during the first year after a positive first-round or 
second-round screen, respectively. Lung cancers 
that were detected during the first year after a 
negative first-round or second-round screening 
test were classified as interval cancers. They were 
identified through linkage with the national pa-
thology database, information from participants 
and general practitioners, and, in the case of 
round-one interval cancers, linkage with the Na-
tional Cancer Registry. The workup, staging, and 
treatment were standard across all screening 
sites and were performed according to published 
guidelines.10,16,17
All the authors contributed to the data collec-
tion and the decision to submit the manuscript 
for publication, and all the authors vouch for the 
accuracy and completeness of the data.
Statistical Analysis
The diagnostic sensitivity was defined as the ra-
tio between the number of true positive results 
(participants who were diagnosed with lung can-
cer during the first year after a positive screening 
test) and the number of true positive results plus 
the number of false negative results (interval 
cancers detected during the same time period). 
Diagnostic sensitivity, specificity, positive predic-
tive value, and negative predictive value were cal-
culated at the participant level, and 95% confi-
dence intervals were determined with the use of 
SPSS software, version 15.0 (SPSS). The standard 
for a negative baseline or second-round test re-
sult was based on the retrospective information 
that lung cancer was absent 2 years after the first 
round of screening and 1 year after the second 
round. Normally distributed data are shown as 
means ±SD. P values of less than 0.05 were con-
sidered to indicate statistical significance.
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R esult s
First Round
The mean (±SD) age of the screened participants 
was 59±6 years, and the mean number of pack-
years smoked was 42±19; a total of 16% of the 
participants were women. The first round of 
screening was conducted from April 2004 through 
December 2006 (Fig. 2 in the Supplementary Ap-
pendix). Of the 7557 participants, 50.5% had a 
total of 8623 noncalcified pulmonary nodules, of 
which 98.0% were solid. Automated volumetric 
data were manually adjusted in the case of 6.3% 
of the nodules. The screening results were deter-
mined to be negative in 5987 participants (79.2%), 
indeterminate in 1451 (19.2%), and positive in 119 
(1.6%) (Fig. 1). A total of 1536 follow-up scans 
were obtained 100±19 days, on average, after the 
baseline scan in participants with an indetermi-
nate result. Including the outcome of these fol-
low-up scans, the results from round one of the 
screening were negative in 7361 participants 
(97.4%) and positive in 196 (2.6%).
Of the 196 participants with a positive scan, 
177 were referred for workup; 19 were not re-
ferred (9 because of a decision by the tumor 
board, 3 because of an administrative error, and 
7 because they were already receiving treatment 
from another specialist). Lung cancer was diag-
nosed in 70 of the 177 participants who had a 
positive scan (39.5%); the diagnosis was made 
mainly by means of an invasive procedure (85.7%). 
These 70 participants had 72 lung cancers, of 
which 46 (63.9%) were classified as pathological 
stage I. In three subjects, no tissue for a histo-
logic diagnosis could be obtained. These subjects 
received high-dose radiotherapy because the le-
sions were growing and were assessed as positive 
on a positron-emission tomographic (PET) scan. 
Of the remaining 107 subjects with a positive 
scan, 100 had benign disease and 7 had metas-
tases from another cancer. In round one, the 
proportion of invasive procedures that revealed 
benign disease was 27.2%.
The lung-cancer detection rate in round one 
was 0.9% (70 of 7557 subjects). There were four 
interval cancers, all of which were stage IV adeno-
carcinomas; three of these were new noncalcified 
nodules, and one, which had been seen in the 
first round, had a volume-doubling time of more 
than 600 days at the 3-month follow-up. The 
sensitivity of round-one screening was 94.6% 
(95% confidence interval [CI], 86.5 to 98.0), the 
specificity 98.3% (95% CI, 98.0 to 98.6), the posi-
tive predictive value 35.7% (95% CI, 29.3 to 42.7), 
and the negative predictive value 99.9% (95% CI, 
99.9 to 100.0). Thus, in a subject with a positive 
CT screening test, the probability that the lesion 
would be malignant was 36%; with a negative 
screening test, the probability that a participant 
would not have lung cancer was 99.9%.
Among the 7361 negative CT scans in round 
one, 20 lung cancers were detected during the 
2 years of follow-up: 3 were round-one interval 
cancers, and 17 were detected in the round-two 
screening. On the basis of this information, the 
negative predictive value was 99.7% (95% CI, 99.6 
to 99.8). All 126 participants with a positive 
screening result at round one but with a negative 
workup returned to the screening program. After 
a mean follow-up of 785±263 days, 10 of these 
126 subjects received the diagnosis of pulmo-
nary adenocarcinoma, which appeared to have 
originated from a suspicious nodule that was 
detected in round one (Table 1 in the Supple-
mentary Appendix).
Second Round
In accordance with the trial’s protocol, all the 
participants in the first round of screening, except 
those in whom lung cancer had been diagnosed, 
were invited to undergo screening in the second 
round,12 which was conducted from April 2005 
through April 2008. A total of 7289 participants 
underwent screening 384±59 days after the round-
one screening (Fig. 1 in the Supplementary Ap-
pendix). In 1588 (21.8%) of these participants, a 
total of 2320 new nodules were detected, 29.2% 
of which had a volume of less than 15 mm3 or 
had been missed in round one. Automated volu-
metric data were manually adjusted in the case of 
5.4% of the new nodules and 1.9% of previously 
existing nodules. The second-round screening 
result was negative in 6719 participants (92.2%), 
indeterminate in 480 (6.6%), and positive in 90 
(1.2%) (Fig. 2). Among participants with an inde-
terminate result, 276 had a follow-up scan 77±36 
days after the second-round screening and 231 
had a follow-up scan 364±36 days after the sec-
ond-round screening. The follow-up scans were 
positive in 38 subjects, and when the results of 
these positive follow-up scans were added to the 
results of the 90 positive screening scans, there 
were 128 subjects (1.8%) with positive second-
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round scans. Of these 128 participants, 1 patient 
died as a result of a metastatic colon carcinoma 
and 118 were referred for workup; 54 of the 118 
who were referred for workup (45.8%) received 
the diagnosis of lung cancer, mainly after under-
going an invasive procedure (88.9%). The nine par-
ticipants who were not referred for workup (four 
because of a decision by the tumor board, four 
because of an administrative error, and one be-
cause the patient was already receiving treatment 
from another specialist) were invited to participate 
in the third round of screening 2 years later. In 
7 col
39p6
5987 Subjects tested negative 
(79.2%)
1395 Benign nodules were found
(16.2% of the 8623 noncal-
cified nodules found in the
total sample)
4861 Nodules <50 mm3 were found
(56.4% of the 8623)
1451 Subjects tested indeterminate 
(19.2%)
2236 Nodules 50 to 500 mm3 were found
2101 Were solid (24.4% of the 
8623 nodules found in the
total sample)
57 Were partially solid (0.7% of 
the 8623)
78 Were nonsolid (0.9% of the 8623)
119 Subjects tested positive 
(1.6%)
131 Nodules >500 mm3 were found
126 Were solid (1.5% of the 8623
nodules found in the total
sample)
5 Were partially solid (0.1% of
the 8623)
7361 Subjects tested negative
(97.4%)
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196 Subjects tested positive
(2.6%)
19 Were not referred for
workup and diagnosis
177 Were referred for workup
and diagnosis
107 Had benign disease or
other cancer
10 Had lung cancer at later rounds
70 Had lung cancer
33 Subjects had no
follow-up scan (2.3%)
54 Noncalcified nodules
were present (2.4% 
of the 2236 found in 
all those who tested 
indeterminate)





486 Resolved (21.7% of 
the 2236 nodules
found in all those 
who tested indeter-
minate)
1049 Had no growth 
         (46.9% of the 2236)
518 Had VDT ≥400 days







followed up (5.8% 
of the 2236 nodules 
found in all those 
who tested indeter-
minate)
Figure 1. Results of the First Round of Screening.
Some participants had more than one nodule. VDT denotes volume-doubling time.
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one of these nine, lung cancer was found 23 
months after the first detection of the nodule in 
a nodule that had not been seen previously. Of 
the remaining 64 subjects with a positive scan, 
62 had benign disease and 2 had another cancer 
(1 a thymoma and 1 lymphoma).
There were two subjects with suspicious le-
sions from whom no tissue could be obtained for 
histologic diagnosis. These subjects were treat-
ed with high-dose radiotherapy because the le-
sions were new and growing and were positive on 
a PET scan. The 54 participants with lung cancer 
7 col
39p6
6719 Subjects tested negative (92.2%)
267 Benign nodules were found (11.5%
of the 2320 new nodules found in the
total sample)
1493 New nodules <50 mm3 were found
(64.4% of the 2320)
9048 Existing noncalcified nodules were
found
549 Were not followed up with  
scanning (5.9% of the 9282 existing
nodules found in the total sample)  
2432 Resolved (26.2% of the 9282)
3638 Did not grow (39.2% of the 9282)
2429 Had VDT >600 days (26.2% of 
the 9282)
480 Subjects tested indeterminate (6.6%)
503 New noncalcified nodules 50 to 500
mm3 were found 
473 Were solid (20.4% of the 2320 new
nodules found in the total sample)
12 Were partially solid (0.5% of the
2320)
18 Were nonsolid (0.8% of the 2320)
163 Existing noncalcified nodules with VDT
400 to 600 days were found (1.8% of 
the 9282 in the total sample)
90 Subjects tested positive (1.2%)
57 New noncalcified nodules >500 mm3
were found
56 Were solid (2.4% of the 2320 new
nodules found in the total sample)
1 Was partially solid (0.0%) 
71 Existing noncalcified nodules with VDT
<400 days were found (0.8% of the 
9282 in the total sample)
128 Subjects tested positive (1.8%)
1 Died
9 Were not referred for
workup and diagnosis
118 Were referred for workup
and diagnosis
64 Had benign disease or
other cancer
54 Had lung cancer
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were present (13.1% 
of the 666  
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230 Resolved (34.5% 
       of the 666 
noncalcified nodules 
found in subjects 
who tested indeter-
minate)
133 Did not grow 
       (20.0% of the 666)
178 Had VDT ≥400 days




38 Noncalcified nodules 
     were followed up
35 Had VDT <400 
days (5.3% of 
the 666 
noncalcified nodules
found in subjects 
who tested indeter-
minate)
3 Had VDT ≥400 days 
(0.5% of the 666)
Figure 2. Results of the Second Round of Screening.
Some participants had more than one nodule. VDT denotes volume-doubling time.
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had 57 cancerous nodules, 42 of which (73.7%) 
were classified as pathological stage I, including 
3 that were synchronous double tumors. The 
lung-cancer detection rate was 0.5% (40 of 7289) 
during the first year after the second-round 
screening and 0.8% (57 of 7289) for the entire 
2-year period after the second and third rounds 
of screening. One stage IV small-cell and one 
stage IV large-cell interval carcinoma, both of 
which were present in nodules that had been 
absent at the time of the second-round screen-
ing, were diagnosed during the first year after 
the second-round screening. The sensitivity of the 
second-round screening was 96.4% (95% CI, 86.8 
to 99.1), the specificity was 99.0% (95% CI, 98.7 
to 99.2), the positive predictive value was 42.2% 
(95% CI, 33.9 to 50.9), and the negative predic-
tive value was 99.9% (95% CI, 99.9 to 100.0).
Additional Diagnostic Investigations
The recall rates for CT scans among participants 
with indeterminate test results were 19.0% and 
3.8% in rounds one and two, respectively (Table 2 
in the Supplementary Appendix). No diagnostic 
PET or PET–CT scanning was performed in par-
ticipants with positive test results, and fine-nee-
dle biopsy procedures were performed in less than 
1% of the subjects. The rate of invasive diagnostic 
procedures was 1.2% in round one and 0.8% in 
round two.
Discussion
In a population that was at an increased risk for 
lung cancer, our strategy of screening for lung 
cancer with the use of volume CT diminished the 
need for follow-up evaluation in participants with 
an indeterminate test result. This strategy was 
especially useful during the second-round screen-
ing. It reduced the number of follow-up examina-
tions in participants with a positive test result 
without reducing the overall sensitivity of the 
technique, as compared with that reported in the 
literature.4-8,18-23 This report concerns itself only 
with how to deal with an abnormality that has 
been detected on a CT scan in this population; it 
does not address the usefulness of screening for 
lung cancer with the use of CT scanning.
The rate of interval cancers that were found 
in participants in our trial was similar to that 
found in participants in other trials.20 The pro-
portion of early (stage I) lung cancers detected 
in round one (63.9%) was similar to that found in 
other randomized trials,18,19,23 but lower than 
that found in nonrandomized trials (e.g., the pro-
portion in the International Early Lung Cancer 
Action Program [I-ELCAP] was 86%, and the 
proportion in a trial performed at the Mayo 
Clinic was 75%).6,7,20 The lung-cancer detection 
rate in round one in I-ELCAP was higher than 
that in NELSON (1.3% vs. 0.9%),7 despite similar 
median ages of the participants and a higher 
number of pack-years smoked by participants in 
NELSON. The discrepancy was probably due to 
the fact that the proportion of women, who tend 
to have slow-growing cancers,24,25 was higher in 
I-ELCAP than in NELSON. Moreover, in I-ELCAP 
surgeons removed any nonsolid nodule that was 
larger than 8 mm, instead of waiting for the 
nodule to grow before removing it, as was done 
in NELSON. In our trial of subjects who had an 
increased risk of lung cancer, we found that the 
chances of finding lung cancer on a CT scan at 
3 months, 1 year, and 2 years after a negative 
first-round test were 0, 1 in 1000, and 3 in 1000, 
respectively.
In round one, the proportion of invasive 
procedures that revealed benign disease was 
27.2%, which is similar to that found in other 
trials.5,6,19,21,22,26-30 The advantages of volumetric 
measurements become fully apparent when a 
volumetric comparison can be made with a pre-
vious indeterminate CT scan. Because there were 
no comparative CT scans available at round one, 
the first-round recall rate was almost as high as 
that in other trials (Table 2 in the Supplemen-
tary Appendix). The LungCare software version 
that we used is not proprietary and can be used 
with any CT data set, regardless of the CT system, 
for evaluation of solid nodules and the solid 
component of partially solid noncalcified nodules 
smaller than 500 mm3. With manual correction, 
the mean relative deviation from the true lesion 
volume was only −0.3±6.5% for these types of 
lesions.13
As an absolute standard for negative test 
results, we used the absence of lung cancer after 
2 years of follow-up, a period that is considered 
to be sufficient for concluding that a nodule is 
benign.2 The 400-day threshold for volume-
doubling time that we used was based on current 
opinion that lung cancers with a volume-doubling 
time of 400 days or more are overdiagnosed 
cases.24,31 A volume-doubling time of 500 days 
Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
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is regarded as the upper limit for lung cancer, 
even though some tumors may grow more slow-
ly32-34; our upper limit was set at 600 days. If a 
lower upper limit had been used, the rate of false 
negatives would have increased, but the rate of 
false positives would have decreased. Therefore, 
the ranges for volume-doubling time that we 
used are not definite and could be improved. 
Finally, before we can make clinically directive 
recommendations, our strategy requires valida-
tion in an independent study.
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